Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre randomised phase II clinical trial of Inotuzumab Ozogamicin plus Rituximab and CVP (IORCVP) versus Gemcitabine plus Rituximab and CVP (GemRCVP) for the first line treatment of patients with diffuse large B cell lymphoma who are not suitable for anthracycline containing chemotherapy

Trial Profile

A multicentre randomised phase II clinical trial of Inotuzumab Ozogamicin plus Rituximab and CVP (IORCVP) versus Gemcitabine plus Rituximab and CVP (GemRCVP) for the first line treatment of patients with diffuse large B cell lymphoma who are not suitable for anthracycline containing chemotherapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2019

At a glance

  • Drugs Inotuzumab ozogamicin (Primary) ; Cyclophosphamide; Gemcitabine; Prednisolone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma; Lymphoma
  • Focus Therapeutic Use
  • Acronyms INCA
  • Most Recent Events

    • 16 Apr 2019 Status changed from recruiting to active, no longer recruiting.
    • 11 Feb 2019 Planned End Date changed from 1 Apr 2021 to 1 Sep 2021.
    • 11 Feb 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top